

Pharmstandard Confirms Purchase of Rival

By The Moscow Times

August 12, 2013



Russian drugmaker Pharmstandard has agreed to buy a supplier of ingredients for its flagship anti-viral and anxiety drugs for \$590 million, as part of a plan to spin off its over-the-counter business.

The plan to purchase Singapore's Bever Pharmaceutical prompted a sell-off in Pharmstandard's shares when it was first announced in July. Analysts were concerned about a lack of information regarding Bever or a clear reason for the deal. Pharmstandard shares are trading 25 percent below their price prior to the deal's announcement.

Pharmstandard said Tuesday that it would pay \$542 million in shares and \$48 million in cash to buy Bever from Pharmstandard board member Alexander Shuster, who will become Pharmstandard's second-largest shareholder with an 18.7 percent stake.

(Reuters)

Original url:

https://www.themoscowtimes.com/2013/08/12/pharmstandard-confirms-purchase-of-rival-a26734